TWiV 914: COVID-19 clinical update #121 with Dr. Daniel Griffin
In COVID-19 clinical update #121, Dr. Griffin discusses age as a risk factor for severe disease, updated vaccine boosters for the fall, pediatric infection and antibody seroprevalence in Arkansas over the first year of the COVID-19 pandemic, all-cause maternal mortality in the United States before and during the pandemic, and the effect of 2-week interruption in methotrexate treatment and how it impacts vaccine immunity. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Age as a risk factor for severe disease (NY Times) Omicron boosters for the fall (NPR) P...
Source: This Week in Virology - MP3 Edition - July 2, 2022 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
TWiV 764: COVID-19 clinical update #65 with Dr. Daniel Griffin
In COVID-19 clinical update #65, Daniel Griffin summarizes effects of non-pharmaceutical interventions, updated summer camp guidance from CDC, serology testing not recommended by FDA, antigen tests during a music event, inhibition of vaccine immunogenicity by methotrexate, phase 3 trial results for colchicine, and small airway disease as a post-acute sequelae. Hosts: Daniel Griffin and Vincent Racaniello Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Effects of vaccines and NPIs (JAMA) Guidance on summer camps (CDC) Antibody testing not recommended (FDA) Antige...
Source: This Week in Virology - MP3 Edition - June 5, 2021 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
Mycophenolate vs Methotrexate for Uveitis, Home-Based Physical Therapy After Hip Fracture, Dialysis Facility Ownership Profit Status and Kidney Transplantation, and more
September 10, 2019 edition of the weekly JAMA Editors' Summary (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - September 10, 2019 Category: General Medicine Authors: JAMA Network Source Type: podcasts
LUX-Head & Neck-1 trial with Afatinib Results #hncs16
Ezra Cohen, MD of the University of California at San Diego discusses the results of the LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent...
Author: ASTROHN2016
Added: 02/23/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 24, 2016 Category: Cancer & Oncology Source Type: podcasts
Subgroup analysis of phase 3 LUX-H&N1 trial: Afatinib versus methotrexate for head and neck squamous cell carcinoma
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Makoto Tahara, MD, PhD, from National Cancer Center Hospital East, Kashi...
Author: EMJ
Added: 02/20/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 20, 2016 Category: Cancer & Oncology Source Type: podcasts
LUX-H&N1: Phase 3 trial of afatinib versus methotrexate for head and neck squamous cell carcinoma
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from The University of Chicago Medicine, Chicago, IL...
Author: EMJ
Added: 02/01/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 1, 2016 Category: Cancer & Oncology Source Type: podcasts
Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis
Alongside Cochrane Reviews of the effects of treatments for particular conditions, there are some that look for ways to reduce the side effects of otherwise effective treatments. Bev Shea, from the University of Ottawa in Canada describes an updated review from May 2013 doing this for the use folic acid or folinic acid with methotrexate for people with rheumatoid arthritis. (Source: Podcasts from The Cochrane Library)
Source: Podcasts from The Cochrane Library - August 26, 2013 Category: Journals (General) Authors: The Cochrane Collaboration Tags: Issues 4 to 6, April to June 2013 Source Type: podcasts
